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Edited by Ned ManteiAbstract Vascular endothelial growth factor (VEGF) and pla-
cental growth factor (PlGF) are key angiogenic stimulators dur-
ing normal development and wound healing, as well as in a
variety of pathological conditions. Recent studies have demon-
strated a synergistic eﬀect of VEGF and PlGF in pathological
angiogenesis and suggest a role for PlGF in amplifying VEGF
action in endothelial cells. We show here in the mouse model
of oxygen-induced retinopathy that VEGF is signiﬁcantly in-
creased (P < 0.01) in the retina at both the mRNA and protein
levels. In this mouse model, PlGF was signiﬁcantly upregulated
in the retina at the protein level (P < 0.01) without a correspond-
ing change in mRNA levels. In cultured human retinal and umbil-
ical vein endothelial cells, VEGF induced the production of PlGF
protein by over 10-fold (P < 0.01) in a dose-dependent manner
through a post-transcriptional mechanism. The increased PlGF
expression upon VEGF treatment was signiﬁcantly reduced by
inhibition of the protein kinase C (PKC) and MEK signaling
pathways, as well as by treatment with the calcium ionophore
A23187. Taken together, our ﬁndings demonstrate that VEGF
can amplify its eﬀects on endothelial cells by inducing the pro-
duction of PlGF via a post-transcriptional mechanism in a
PKC-dependent manner, and provide a potential link between
PKC inhibition and amelioration of vascular complications in
the development of angiogenic diseases.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The role of growth factors in angiogenic disorders includ-
ing retinal neovascularization has received great attention.
Although many factors are likely to be important in the
development of retinal neovascularization, it is clear that vas-
cular endothelial growth factor (VEGF), in particular, plays a
major role. Intraocular VEGF levels are signiﬁcantly in-Abbreviations: VEGF, vascular endothelial growth factor; PlGF, pla-
cental growth factor; HUVEC, human umbilical endothelial cell;
HREC, human retinal endothelial cell
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doi:10.1016/j.febslet.2005.01.017creased in patients with retinal neovascularization [1,2]. In
animal models of ischemic retinopathy, VEGF expression
correlates temporally and spatially with ocular neovasculari-
zation [3,4]. Increased expression of VEGF in the retina is
suﬃcient to cause retinal and subretinal neovascularization
[5], whereas inhibition of VEGF or VEGF signaling signiﬁ-
cantly reduces retinal neovascularization in animal models
[6–10].
In addition to VEGF, however, other factors are likely to
play a signiﬁcant role in retinal neovascularization, and may
therefore serve as additional targets for therapy. Placental
growth factor (PlGF) has emerged as an important pro-
angiogenic factor. PlGF is a member of the ‘‘VEGF family’’
of structurally related growth factors [11]. Unlike VEGF-A
(which binds both VEGFR-1 and VEGFR-2), PlGF speciﬁ-
cally binds VEGFR-1. Studies of PlGF-deﬁcient mice have
demonstrated that PlGF is required for pathologic angiogen-
esis, including retinal [12] and choroidal neovascularization
[13]. Such studies have also demonstrated an important role
for PlGF in plasma extravasation and collateral vessel
growth during ischemia and wound healing [12], as well as
inﬂammation [12,14]. PlGF has been found to stimulate
angiogenesis and collateral growth in ischemic heart and
limb with an eﬃciency comparable to that of VEGF
[12,15,16].
PlGF and VEGF have been demonstrated to play a syner-
gistic role in pathologic angiogenesis [12], and PlGF is thought
to ‘‘amplify’’ VEGF-driven angiogenesis and activation of vas-
cular endothelial cells [12,17]. PlGF could therefore represent
an additional and perhaps safer target (given its binding spec-
iﬁcity for VEGFR-1), for the treatment of neovascular disor-
ders [18].
In this study, we sought to further explore the potential
role of PlGF in retinal neovascularization by investigating
the expression of PlGF both in vivo and in vitro. We found
a signiﬁcant increase in PlGF protein in mouse retinal tissue
during neovascularization, which accompanied an increase in
VEGF levels. We further studied the regulation of PlGF pro-
duction in cultured endothelial cells and found that PlGF is
upregulated by VEGF and phorbol-12-myristate-13-Acetate
(PMA). While PMA increased PlGF mRNA, VEGF upregu-
lation of PlGF was at the protein level and was dependent on
the protein kinase C (PKC) signaling pathway, thus repre-
senting a potentially novel mechanism of regulation by
VEGF. Our results suggest that VEGF can amplify its eﬀects
on endothelial cells by inducing endothelial cell production of
PlGF.ation of European Biochemical Societies.
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2.1. Animal studies
Oxygen-induced retinopathy was elicited in mice as previously de-
scribed [19]. In brief, postnatal day 7 (P7) C57BL/6J mice were exposed
to 75% O2, along with their nursing mother for 5 days. On P12, the
mice were returned to room air. The mice were sacriﬁced at the indi-
cated times. Retinas were extracted, snap-frozen in liquid nitrogen,
and stored at 80 C until further processing. For ELISA studies, total
protein was harvested as previously described [20]. RNA was extracted
from retinas using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturers instructions.2.2. Cell culture
Human umbilical endothelial cells (HUVECs, Clonetics Corpora-
tion, San Diego, CA) and human retinal endothelial cells (HRECs,
Cell Systems, Inc., Kirkland, WA) were cultured in EGM2-MV med-
ium (Clonetics Corporation, San Diego, CA) and used between pas-
sages 4 and 10. HRECs were cultured on ﬁbronectin-coated dishes
or plates. Cells were grown to conﬂuence in EGM2-MV medium in
12-well plates and washed with phosphate-buﬀered saline, switched
to Dulbeccos modiﬁed Eagles medium (DMEM) containing 10% calf
serum (CS), and treated with the following stimulators and/or signal-
ing pathway inhibitors: human recombinant VEGF, TNF-a, and basic
ﬁbroblast growth factor (bFGF) were purchased from R&D Systems,
Inc. (Minneapolis, MN); PD98059, U0126, GF109203X, Calphostin
C, SB203580, LY294002, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine), cyclosporin A, and PMA were pur-
chased from CalBiochem (San Diego, CA). LY333531, a speciﬁc
PKCb isoform inhibitor, was from A.G. Scientiﬁc, Inc. (San Diego,
CA). Culture medium was collected at the indicated time points and
stored at 20 C. Cells were harvested in Trizol and total RNA was
isolated according to the manufacturers instructions.2.3. ELISA assay
PlGF levels in cell culture supernatants and lysates were measured
by the Quantikine PlGF assay kit (R&D Systems) according to the
manufacturers instructions. Serial dilutions of recombinant human
PlGF were included in all assays to serve as a standard. In our hands,
this assay has a limit of sensitivity of 15.625 pg/ml. ELISA assay of re-
combinant human VEGF (100 ng/ml) using the Quantikine PlGF as-
say kit demonstrated no cross-reactivity, consistent with the
manufacturers speciﬁcations (R&D Systems). The VEGF and PlGF
concentrations in mouse retina samples were detected using the mouse
VEGF and PlGF-2 Quantikine ELISA kits, respectively (R&D Sys-
tems).2.4. Northern blot and quantitative real-time PCR
For Northern blot analysis, samples of RNA (20 lg per lane) were
size-fractionated on 1% agarose–formaldehyde gel, transferred onto
a Gene Screen Hybridization transfer membrane (NEN Life Science),
and UV crosslinked. After prehybridization for 2 h at 42 C, the mem-
brane was hybridized with 32P-labeled PlGF probe overnight. The
probe was a 738-bp fragment (residing in the 3 0-UTR of PlGF) puriﬁed
from the NotI/EcoRI digested products of IMAGE Clone 2141182 and
labeled using Prime It II Random Prime Labeling Kit (Stratagene).
The blot was then washed three times, for 20 min at 42 C, and ex-
posed to Imaging Screen K-HD (Bio-Rad, Hercules, CA) for 24 h at
80 C.
Single-stranded cDNA was synthesized from 1 to 2 lg total RNA
using an oligo(dT) 18mer as primer and the M-MLV Reverse Trans-
criptase (Promega Corp.) in a ﬁnal reaction volume of 25 ll. Real-time
PCR for human PlGF was performed with the QuantiTect SYBR
Green PCR Kit (Qiagen Inc.) and LightCycler system (Roche
Diagnostics Corporation) by using primer pair f581 (5 0-GTTCAGCC-
CATCCTGTGTCT-3 0)/r668 (5 0-TTAGGAGCTGCATGGTGACA-
3 0), which targets exon 3 of PlGF and is present in all PlGF isoforms
[21,22], according to human BLAT search (http://www.genome.ucsc.e-
du/cgi-bin/hgBlat). A thermal cycle at 95 C for 15 min was used prior
to cycling to activate the HotStarTaq DNA Polymerase, then followed
by 30 cycles at 94 C for 15 s, 55 C for 20 s; and 72 C for 10 s. Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was ampliﬁed as
described [23] and used as the reference for normalization. Real-timePCR for mouse VEGF was performed using primer pair mVEGF-F
(5 0-TTACTGCTGTACCTCCACC-3 0)/mVEGF-R (5 0-ACAGGACG-
GCTTGAAGATG-3 0) [24]. Real-time PCR for mouse PlGF was
performed using primer pair mPGF-1198F (5 0-TGAAGGCATG-
TAGAGGGGAC-3 0)/mPGF-1370R (5 0-CACTCTGCCTGTGTTC-
CAGA-3 0), which is located in exon 7 of mouse PlGF. Murine genes
were normalized to mouse GAPDH, which was ampliﬁed using primer
pair GAPDH-F (5 0-AACGACCCCTTCATTGAC-3 0)/GAPDH-R (5 0-
TCCACGACATACTCAGCAC-3 0).2.5. Statistical analyses
All experiments were performed at least three times and results were
expressed as means ± S.E. Statistical diﬀerences were assessed by the
two-tailed t-test. A value of P < 0.05 was considered as statistically sig-
niﬁcant.3. Results
3.1. Increased PlGF protein, but not mRNA levels, in mouse
oxygen-induced retinopathy model
We investigated PlGF and VEGF protein and mRNA levels
in the mouse model of oxygen-induced retinopathy [19]. In this
experimental model, C57BL/6 mice are exposed to high oxygen
from postnatal day 7 (P7) to P12, which results in extensive
retinal capillary obliteration. On return of these mice to room
air on P12, the inner retina becomes relatively hypoxic, which
results in the formation of retinal neovascularization in 100%
of animals by P17 [19]. Retinal VEGF mRNA expression
has been found to be signiﬁcantly increased in this model
beginning at P12.5 [4].
In our experiment, there was a signiﬁcant increase of retinal
VEGF at both the mRNA and protein levels in P13 mice com-
pared with P12 mice (P < 0.01), and the increased level of
VEGF was maintained on P16 (Fig. 1). In addition, the mouse
PlGF protein in the retina increased in a similar pattern to that
of VEGF. However, real-time PCR for mouse PlGF revealed
no increase of PlGF mRNA, and the mRNA level at P13
was actually slightly decreased compared with P12 (Fig. 1). Ta-
ken together, our results indicate that the increase of PlGF is
regulated at the protein level.3.2. VEGF increases PlGF protein production in cultured
endothelial cells
Endothelial cells are known to be an important source of
PlGF [18,25]. We postulated that regulation of endothelial cell
PlGF production might contribute to increased PlGF levels in
mouse retina during neovascular conditions. Since VEGF is a
major regulator of endothelial cells and we observed a correla-
tion between PlGF and VEGF levels in mouse retina, we tested
the kinetics of PlGF production in response to VEGF treat-
ment in cultured HUVECs and HRECs. We collected the cul-
ture medium at designated time points and determined PlGF
levels by ELISA. The concentration of PlGF in the culture
supernatant showed a time-dependent change, with increase
after 4 h VEGF treatment and peak increase after 24 h of
VEGF stimulation (Fig. 2(a)). The regulation of PlGF produc-
tion by VEGF was dose-dependent. VEGF at 2.5 ng/ml
slightly increased PlGF compared with untreated controls.
PlGF production was signiﬁcantly upregulated by VEGF at
25 ng/ml, and upregulation of PlGF reached a plateau at a
VEGF concentration of 100 ng/ml (Fig. 2(a)), with at least
10-fold increased PlGF production (Fig. 2(b) and (c)). We also
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Fig. 1. VEGF and PlGF levels in mouse model of oxygen-induced
retinopathy. (a) VEGF and PlGF protein concentrations and (b)
VEGF and PlGF mRNA expression in mouse retinas detected by
ELISA assay and quantitative real-time PCR, respectively. \\P < 0.01
vs. controls (postnatal day 12, P12). P < 0.05 vs. PlGF mRNA level in
controls. Three mice were used for each time point.
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Fig. 2. VEGF induces PlGF production in cultured HUVECs and
HRECs. (a) Time-course of PlGF protein in HUVEC supernatant in
response to VEGF (100 ng/ml) stimulation. Dose-dependent regula-
tion of PlGF production induced by 24 h VEGF treatment in the
culture supernatant of (b) HUVEC and (c) HREC. (d) PlGF
concentrations in HUVEC culture supernatant stimulated by bFGF
(25 ng/ml) and TNF-a (25 ng/ml). Cells were grown to conﬂuence in
EGM-2MV in 12-well plates, then switched to 500 ll DMEM
containing 10% CS and the indicated concentration of VEGF after
washing with PBS. Culture supernatant was collected at indicated time
points and PlGF levels measured by ELISA. The results shown are
representative of four independent experiments, each performed in
duplicate. \\P < 0.01 vs. controls.
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sate (data not shown). The upregulation of PlGF in endothe-
lial cells was speciﬁc for VEGF, as PlGF levels in the culture
supernatant were not signiﬁcantly changed by treatment with
bFGF (25 ng/ml) or TNF-a (25 ng/ml) for 24 h using the same
culture conditions (Fig. 2(d)).
3.3. VEGF stimulation does not alter PlGF mRNA levels in
cultured endothelial cells
In order to determine whether VEGF upregulation of PlGF
protein was accompanied by an increase in PlGF mRNA lev-
els, HUVECs were treated with diﬀerent concentrations of
VEGF for 24 h. Cells were harvested at the indicated time
points and total RNA was isolated. Similar to the ﬁndings in
the mouse retina studies, real-time PCR for PlGF revealed that
PlGF mRNA levels did not change signiﬁcantly in either HU-
VEC or HREC treated with diﬀerent doses of VEGF (Fig. 3(a)
and (b)). This result was further conﬁrmed by Northern blot
Fig. 3. PlGF mRNA expression is not altered by VEGF treatment.
Quantitative real-time PCR for PlGF mRNA in HUVECs (a) and
HRECs (b) in response to diﬀerent concentrations of VEGF. PlGF
mRNA values were normalized to GAPDH gene expression and were
demonstrated as means ± S.E.M. (c) Northern blot analysis of PlGF
mRNA levels in HUVECs with or without 24 h VEGF (100 ng/ml)
treatment. Results are representative of two independent experiments,
each performed in duplicate.
1230 Y.-G. Yao et al. / FEBS Letters 579 (2005) 1227–1234analysis for PlGF mRNA (Fig. 3(c)). Therefore, our results
suggest that PlGF production in response to VEGF is via a
post-transcriptional mechanism.
3.4. PKC signaling is involved in the VEGF induction of PlGF
In order to characterize which signaling pathway(s) are in-
volved in the upregulation of PlGF by VEGF treatment, we
incubated conﬂuent HUVEC and HREC in DMEM contain-
ing 10% CS together with VEGF (100 ng/ml) and signaling
pathway inhibitors for 24 h. Inhibition of p38 MAP kinase
(SB203580, 10 lM), phosphatidylinositol 3-kinase (PI 3-ki-
nase: LY294002, 20 lM), src family of tyrosine kinases
(PP2, 3 lM), and protein phosphatase activity of calcineurin
(protein phosphatase 2B, PP2B; cyclosporin A, 1 lM),
respectively, slightly aﬀected PlGF production comparedwith VEGF treatment alone, but the diﬀerence was not sta-
tistically signiﬁcant (Fig. 4(a)). The inhibition eﬀect of each
inhibitor at the designated concentration was tested by
dephosphorylation of its respective signaling target (data
not shown). Therefore, it appears that these signaling path-
ways are not playing a crucial role in the upregulation of
PlGF by VEGF. Intriguingly, the PlGF concentration was
signiﬁcantly reduced by the Ca2+ ionophore, A23187
(1 lM) (Fig. 4(a)). PlGF concentrations in the culture super-
natant were signiﬁcantly reduced when the PKC (Calphostin
C, 2.5 lM; GF109203X, 3 lM) and MEK (mitogen-activated
protein kinase kinase: U0126, 10 lM; PD98059, 50 lM) sig-
naling pathways were blocked (P < 0.05). The inhibition of
the PKC signaling pathway showed a dose-dependent eﬀect,
whereas the inhibition of MEK was not sensitive to the
inhibitor concentrations tested (Fig. 4(b) and (c)). Interest-
ingly, inhibition of the PKCb isoform by LY333531 also re-
duced the PlGF production in a dose-dependent fashion
(Fig. 4(d)). This suggests that the PKC signaling pathway
plays an important role in the increased PlGF production in-
duced by VEGF.
3.5. PMA upregulates PlGF mRNA and protein levels
Since the PKC signaling pathway was found to be important
for PlGF production by endothelial cells, we speculated that
PMA, aPKCactivator even at nanomolar concentrations, could
have a stimulatory eﬀect on the production of PlGFprotein. The
incubation of HUVEC and HREC with VEGF (100 ng/ml) and
PMA (100 ng/ml) had a synergistic eﬀect on PlGF production,
greater than 3-fold higher than VEGF (100 ng/ml) treatment
alone (P < 0.01). PMA alone at concentrations of 10 and
100 ng/ml also signiﬁcantly induced the production of PlGF in
the culture supernatant, comparable to that of VEGF (100 ng/
ml) alone. In addition, PMA stimulation at a low concentration
(10 ng/ml) resulted in a higher PlGFprotein level comparedwith
a high PMA concentration (100 ng/ml) (Fig. 5(a)).
In parallel with its stimulating eﬀects on PlGF protein levels,
PMA upregulated RNA levels of PlGF by at least 4-fold
(P < 0.01) (Fig. 5(b)). VEGF did not have a synergistic eﬀect
with PMA on PlGF mRNA levels (Fig. 5(b)), although VEGF
did have a synergistic eﬀect with PMA on PlGF protein levels
(Fig. 5(a)). This result gives further support that VEGF upreg-
ulates PlGF protein at a post-transcriptional (protein) level,
and that the PKC signaling pathway plays an active but com-
plex role in PlGF expression.4. Discussion
VEGF and PlGF are key angiogenic stimulators for normal
and pathological angiogenesis. By binding to its two main
receptor tyrosine kinases, Flt1 (VEGFR1) and KDR
(VEGFR2, serving as the major signaling receptor), VEGF in-
duces angiogenesis and plays a critical role in embryonic vas-
cular development, physiologic angiogenesis, and a variety of
pathological conditions including tumor growth and blinding
eye conditions such as diabetic retinopathy and age-related
macular degeneration [26,27]. PlGF only binds to Flt1 and
was initially regarded as a decoy factor serving to displace
VEGF from Flt1 to KDR [28]. Recently, a series of studies
showed that loss of PlGF, while not causing any vascular de-
fects during normal development, impaired angiogenesis and
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[12,14,29]. On the other hand, overexpression of PlGF in mice
resulted in a substantial increase of dermal blood vessels, en-
hanced vascular permeability, and increased the inﬂammatory
response [14,30]; it also contributed to the pathogenesis of pul-
monary emphysema [31]. Moreover, PlGF stimulation has
been shown to result in the phosphorylation of diﬀerent tyro-0
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Fig. 5. PMA up-regulates the production of PlGF and has a
synergistic eﬀect with VEGF treatment in HUVECs. \\P < 0.01 vs.
controls. (b) Quantitative real-time PCR for PlGF mRNA in HUVECs
treated with PMA and/or VEGF (100 ng/ml). The results shown are
representative of 3 independent experiments, each performed in
duplicate. \\P < 0.01 vs. untreated control samples.sine residues as compared to VEGF stimulation [17]. PlGF
stimulation of endothelial cells also results in a gene expression
proﬁle distinct from VEGF stimulation. PlGF regulates both
intermolecular and intramolecular cross talk between Flt1
and Flk1, thereby amplifying VEGF-driven angiogenesis
through Flk1 [17]. All these studies suggest that PlGF plays
an important role in pathologic angiogenesis and may be a po-
tential therapeutic target.
In this study, we ﬁrst tested the levels of the pro-angiogenic
molecule PlGF in the murine oxygen-induced retinopathy
model of retinal neovascularization and found a similar pat-
tern of increased VEGF and PlGF levels in mouse retina in re-Fig. 4. (a) Eﬀects of signaling pathway inhibitors on the production of
PlGF protein in response to VEGF treatment. HUVECs were grown
conﬂuent in 12-well plates, incubated with drugs (cyclosporin A, 1 lM;
SB203580, 10 lM; LY294002, 20 lM; PP2, 3 lM; A23187, 1 lM) and
VEGF (100 ng/ml) for 24 h. Culture supernatant was collected, and
PlGF levels measured by ELISA. Results are representative of at least
three independent experiments performed in duplicate. \\P < 0.01 vs.
untreated control samples, P < 0.01 vs. VEGF-treated samples. (b)
Inhibition eﬀects of MAP kinase (b) and PKC (c) signaling pathways
on the production of PlGF protein in response to VEGF (100 ng/ml)
treatment. (d) Inhibition of the PKC beta isoform by speciﬁc inhibitor,
LY333531, shows a dose-dependent eﬀect on the secreted PlGF level
induced by VEGF (100 ng/ml). \\P < 0.01 vs. untreated control
samples. P < 0.05 or P < 0.01 vs. VEGF-treated alone.
b
VEGF
PKC
PlGF
Pathological angiogenesis
Fig. 6. Possible links among VEGF, PKC and PlGF in pathological
angiogenic conditions.
1232 Y.-G. Yao et al. / FEBS Letters 579 (2005) 1227–1234sponse to oxygen-induced retinopathy. This result is consistent
with observations that the vitreous PlGF and VEGF levels are
signiﬁcantly increased in proliferative diabetic retinopathy pa-
tients as compared to non-neovascular disease patients
[1,2,32]. Interestingly, comparison of VEGF and PlGF mRNA
in mouse retina revealed an increase in VEGF mRNA (which
is consistent with a previous study [4]), whereas PlGF mRNA
remained stable (Fig. 1). Our observations of increased PlGF
in mouse retina in association with neovascularization led us
to speculate whether or not the increased PlGF protein level
was a consequence of the increased VEGF.
Since endothelial cells are known to be an important source of
PlGF [18,25], we postulated that regulation of endothelial cell
PlGF production by VEGFmight contribute to increased PlGF
levels during the neovascular process; we investigated this
hypothesis using cultured endothelial cells treated with VEGF.
Indeed, the production of PlGF by both HUVEC and HREC
was upregulated by VEGF in a dose-dependent fashion. Similar
to our ﬁndings inmouse retina during retinal neovascularization
(Fig. 1), the upregulation of PlGF protein was not accompanied
by an increase in PlGF mRNA. This induction of PlGF protein
in cultured endothelial cells was speciﬁc to VEGF and did not
occur with TNF-a or bFGF treatment (Figs. 2 and 3). It should
be mentioned that during preparation of our manuscript, a pa-
per reported that PlGF is upregulated in bovine retinal micro-
vascular endothelial cells at both the RNA and protein level
(approximately 2-fold upregulation of PlGF RNA and protein)
by 100 ng/ml VEGF compared with non-treated control [33]. In
contrast, we observed a dramatic upregulation of PlGF protein
by VEGF without a concomitant increase in PlGFmRNA. It is
conceivable that the diﬀerences in our results are due in part to
the cell types used (HUVEC and HREC) in our studies vs. bo-
vine retinal endothelial cells in the studybyZhao et al. [33].More
important, the cell culture conditions are diﬀerent and may be
contributory, as we used serum-supplemented media for our
experiments; we have found that serum starvation itself can
upregulate PlGF mRNA (data not shown), thereby potentially
blunting any observed eﬀect of VEGF. In addition, we observed
similar results of upregulation of PlGF protein but not RNA in
the mouse retina during retinal neovascularization (Fig. 1),
which supports the concept that upregulation of PlGFbyVEGF
via a post-transcriptional mechanism may be an important bio-
logical phenomenon in pathological angiogenic complications.
Intriguingly, the induction of PlGF by VEGF was signiﬁ-
cantly aﬀected by activation and inhibition of the PKC signal-
ing pathway (Figs. 4 and 5), suggesting that PKC plays an
active role in this process. It is noteworthy that activation of
PKC, especially the b isoform, has been implicated for both
the early and late-stage manifestations of diabetic retinopathy,
and PKC inhibition has been found to slow or reverse the pro-
gression of diabetic retinopathy and diabetic macular edema
[34–39]. A speciﬁc inhibitor of the PKCb isoform,
LY333531, is currently under investigation in clinical trials
for the amelioration of pathological changes associated with
retinal permeability and angiogenesis [38–41]. Oral administra-
tion of LY333531 ameliorates the retinal mean circulation time
[34], prevents diabetes-induced retinal vascular permeability
[35], and attenuates leukocyte entrapment in the retinal micro-
circulation of diabetic rats [42]. Moreover, mice transgenic for
the PKCb2 isoform develop a dramatic increase in retinal neo-
vascularization in the oxygen-induced retinopathy model,
whereas PKCb knockout mice demonstrate a signiﬁcant de-crease in retinal neovascularization [37]. The eﬀects of activa-
tion or overexpression of PKC in diabetic pathological
complications are similar to the eﬀects observed with PlGF
overexpression, such as increased vascularization, vessel per-
meability, as well as inﬂammatory responses associated with
more pronounced vascular enlargement, edema, and inﬂam-
matory cell inﬁltration [12,14,29,30]. Moreover, inhibition of
PKC has an ameliorating eﬀect on pathologic complications,
similar to that observed for PlGF deﬁciency in mice
[12,14,29,30]. All these results suggest that inhibition of
VEGF-induced increase in PlGF production by PKC inhibi-
tion may be one possible mechanism for the eﬃcacy of
LY333531 in diabetic retinopathy. Indeed, the production of
PlGF in response to VEGF stimulation in endothelial cells
was signiﬁcantly inhibited by LY333531 (Fig. 4(d)). This gives
supportive evidence that PKC is involved in the increased pro-
duction of PlGF in proliferative diabetic retinopathy and other
pathological angiogenesis complications.
The angiogenic switch has been postulated to result from an
imbalance between stimulators and inhibitors of angiogenesis
in a given tissue bed [43]. VEGF is known to be a major angio-
genic stimulator in diverse angiogenic conditions including reti-
nal neovascularization [44]. Indeed, VEGF is known to increase
the expression of several pro-angiogenic genes, including angio-
poietin-2 [45,46], connective tissue growth factor [47,48], tissue
factor [49], COX-2 [50], and IL-8 [51], by increasing RNA levels
of these genes. This mode of VEGF gene regulation at the RNA
level has been further demonstrated by microarray studies of
endothelial cells stimulated with VEGF [52,53]. In this study,
we demonstrate that VEGF upregulates the pro-angiogenic
molecule, PlGF, at the protein level, which supports a versatile
regulatory role for VEGFduring angiogenesis. It is possible that
VEGFmay similarly upregulate other pro-angiogenicmolecules
at the post-transcriptional level. VEGF upregulation of PlGF
serves as a potential mechanism for VEGF augmentation of
its own eﬀects on endothelial cells, since PlGF is known to play
an important role in enhancing VEGF action [12,17], thereby
contributing to the angiogenic switch.
In summary, the signiﬁcant increase in PlGF levels in human
proliferative diabetic retinopathy and the mouse oxygen-in-
duced retinopathy model raises the possibility of an active role
for PlGF in ocular neovascular diseases, particularly in light of
recent studies in PlGF transgenic and knockout mice demon-
Y.-G. Yao et al. / FEBS Letters 579 (2005) 1227–1234 1233strating an important role for PlGF in pathological angiogenic
processes. With respect to retinal neovascularization, studies
of PKC-b knockout mice have demonstrated a signiﬁcant
reduction in neovascularization, a result similar to PlGF
knockout mice. Inhibition of the PKC signaling pathway in
our study signiﬁcantly aﬀected the upregulation of PlGF by
VEGF in cultured endothelial cells. These results provide a po-
tential link between PKC inhibition and amelioration of vascu-
lar complications in the development of pathological
angiogenic conditions (Fig. 6).
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